Outcomes in ANCA-Associated Vasculitis in Scotland: Validation of the Renal Risk Score in a Complete National Cohort

Authors

Dominic P McGovern
Jennifer S Lees
Jamie P Traynor
Bruce Mackinnon
Samira Bell
Robert W Hunter
Neeraj Dhaun
Wendy Metcalfe
Dana Kidder
Michelle Lim
Nicola Joss
Michael Kelly
Alison Taylor
Zoe Cousland
Vishal Dey
Kate Buck
Silke Brix
Colin C Geddes
Emily P McQuarrie
Kathryn I Stevens

Publication Date

8-1-2023

Journal

Kidney International Reports

Abstract

INTRODUCTION: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) causes autoimmune-mediated inflammation of small blood vessels in multiple organs, including the kidneys. The ability to accurately predict kidney outcomes would enable a more personalized therapeutic approach.

METHODS: We used our national renal biopsy registry to validate the ability of ANCA Renal Risk Score (ARRS) to predict end-stage kidney disease (ESKD) for individual patients. This score uses histopathological and biochemical data to stratify patients as high, medium, or low risk for developing ESKD.

RESULTS: A total of 288 patients were eligible for inclusion in the study (low risk

CONCLUSION: The ARRS better discriminates risk of ESKD in AAV and offers clinicians more prognostic information than the use of standard biochemical and clinical measures alone. This is the first time the ARRS has been validated in a national cohort. The proportion of patients with high-risk scores is lower in our cohort compared to others and should be noted as a limitation of this study.

Keywords

ANCA-associated vasculitis (AAV), ANCA Renal Risk Score (ARRS), biopsy registry, end-stage kidney disease (ESKD)

Comments

Supplementary Materials

PMID: 37547534